Introduction {#Sec1}
============

Corona Virus Disease (COVID)-19 is a respiratory viral infection caused by a newly emergent coronavirus, Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2), which started in Wuhan, China, in December 2019 and has since evolved into a pandemic with a global risk to human health \[[@CR1]\]. While the majority of infected patients with COVID-19 have mild or uncomplicated disease, nearly 14% of patients may develop severe symptoms requiring hospitalization and oxygen support, and 5% require aggressive treatment with admission to an intensive care unit (ICU) \[[@CR2]\]. This virus can lead to respiratory, intestinal, and hepatic injury, and may cause acute respiratory distress syndrome (ARDS), septic shock with multi-organ failure, and even death in severe cases \[[@CR3], [@CR4]\]. Fever, dry cough, and shortness of breath are the main clinical manifestations of SARS-CoV-2 infection \[[@CR5]\]. Although abnormal liver enzymes were regularly described as an extrapulmonary clinical feature, and almost one half of patients experienced grades of hepatic injury \[[@CR6]--[@CR9]\], liver damage in patients with SARS infections was primarily manifested in the mild and moderate elevation of alanine and/or aspartate aminotransferases (ALT and AST) with some degree of hypoalbuminemia and hyperbilirubinemia during the early stage of the illness \[[@CR10], [@CR11]\]. The average level of ALT from 56.07 U/L to 111.32 U/L and the average serum albumin from 37.25 g/L to 34.26 g/L at the day of admission throughout the third week after hospitalization, respectively were reported in patients with acute respiratory syndrome \[[@CR12]\]. In this brief review article, we summarized the characteristics and mechanism of liver injury in patients with SARS-CoV-2 infection, with the hope of guiding further study on this important topic.

Methods {#Sec2}
=======

Medline/Pubmed databases were searched thoroughly with search strategies using search keywords "COVID-19", "liver injury", "ICU admission", and "epidemiology", to classify studies published between the years 2019 and 2020. All types of related studies were selected. Adults with COVID-19 infection and liver injury were included. Studies related to non-humans were excluded from our review. All selected articles were reviewed by the authors for relevance to COVID-19 and liver injury.

Epidemiology of liver injury in COVID-19 {#Sec3}
========================================

COVID-19 is a novel infection caused by SARS-CoV-2 and the number of cases is still rapidly growing worldwide \[[@CR13], [@CR14]\]. Current data on COVID-19 have reported that the incidence of abnormal ALT/AST levels varies from 14.8% to 53% \[[@CR15], [@CR16]\]. Patients with more severe COVID-19 appear to have higher rates of hepatitis with elevation of liver enzyme compared with mild to moderate disease (Table [1](#Tab1){ref-type="table"}).Table 1Liver test abnormalities from various Corona Virus Disease (COVID)-19 studiesArticlePatient categoryAST U/LALT U/LALP U/LTotal bilirubin\
μmol/LAlbumin\
g/LPT\
SAPTT\
SYang et al. \[[@CR8]\]Total patient\-\-\-\-\-\--Severe/nonsurvivor\-\--19.1-12.9-Non-severe/survivor\-\--13.1-10.9-Arentz et al. \[[@CR9]\]All patient34(5--40)26.5(5--50)80(31--120)0.6^a^(0--1.5)\-\--Severe/nonsurvivor\-\-\-\-\-\--Non-severe/survivor\-\-\-\-\-\--Chen et al. \[[@CR6]\]Total patient34(15--40)39(9--50)-15.1(0--21)31.6(40--55)11.3(10.5--13.5)27.3(21--37)Non-severe/survivor\-\-\-\-\-\--Severe/nonsurvivor\-\-\-\-\-\--Wu et al. \[[@CR11]\]Total patient30(15--40)24(9--50)-6.6(0--21)38(40--55)10.6(10.5--13.5)18.6(21--37)Severe/nonsurvivor\-\-\-\-\-\--Non-severe/survivor\-\-\-\-\-\--Qian et al. \[[@CR14]\]Total patient21(15--40)18(9--50)\--40(40--55)\--Severe/nonsurvivor2719.9\--38.8\--Non-severe/survivor2118\--4.2\--Wang et al. \[[@CR7]\]Total patient31(15--40)24(9--50)-9.8(5--21)-13(9.4--12.5)31.4(25.1--36.5)Severe/nonsurvivor5235-11-13.230.4Non-severe/survivor2923-9.3-12.931.7Lo et al. \[[@CR15]\]Total patient20(\< 41)24(\< 40)-6(0--24)-12.2(12.2)34.5(30)Severe/nonsurvivor24\-\-\-\-\--Non-severe/survivor19\-\-\-\-\--Huang et al. \[[@CR16]\]Total patient-32-11.731.411.127Severe/nonsurvivor-49-1427.912.226.2Non-severe/survivor-27-10.834.710.727.7Data is mean (SD) or median (interquartile range \[IQR\]) depending on the original study with normal range in the parentheses. ^a^mg/dL. *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *ALP* alkaline phosphatase, *U/L* units per litre, *PTS* prothrombin time in seconds, *APTTS* activated partial thromboplastin time in second

In a prospective study, Huang et al. reported elevation of AST in eight (62%) of 13 patients in the ICU compared with seven (25%) of 28 patients who did not require medical treatment in the ICU \[[@CR16]\]. Additionally, Guan et al. showed that 39.4% of patients with severe COVID-19 requiring ICU admission and mechanical ventilation had AST \> 40 U/L compared with 18.2% of non-severe cases \[[@CR17]\]. In the multicenter retrospective study, the mean level of AST and ALT in 32 patients was significantly higher compared with controls \[[@CR18]\]. The majority of patients had elevated AST/ALT; however, Chan et al. documented a cholestatic pattern of liver injury, with elevation in alkaline phosphatase to 211 U/L in one out of seven patients infected with the virus \[[@CR19]\]. In a retrospective study, Xie et al. described that in 79 COVID-19 non-ICU patients, transaminase elevation was more common in male patients who also had leukocytosis, elevated C-reative protein (CRP), and more lesions in lung by computerized tomography (CT) scan with a longer length of stay in hospital (*p* \< 0.05) \[[@CR20]\]. In concordance with the previous study, patients with hepatic injury had higher inflammatory markers, such as elevated CRP and reduced absolute numbers of lymphocytes such as T cells, and in severe cases of COVID-19, hepatic injury was complicated by greater activation of coagulation and fibrinolytic pathways \[[@CR7], [@CR21], [@CR22]\].

Liver injury and severity of COVID-19 {#Sec4}
=====================================

A study in China showed that COVID-19 patients with abnormal liver enzyme of hepatocellular or mixed types (elevated ALT/AST, or both ALT/AST and ALP/gamma-glutamyl transpeptidase \[GGT\]) had higher odds of progression to severe COVID-19 compared with patients with normal liver tests (odds ratios 2.73; 95% confidnec interval \[CI\] 1.19--6.3, and 4.44, 95% CI 1.93--10.23, respectively) \[[@CR23]\]. Additionally, in a systematic review and meta-analysis of 20 retrospective studies with 3428 COVID-19 patients (severe cases = 1455 and mild cases = 1973), higher serum levels of AST (weighted mean difference = 8.84 U/L, 95% CI = 5.97 to 11.71, *p* \< 0.001), ALT (weighted mean difference = 7.35 U/L, 95% CI = 4.77 to 9.93, *p* \< 0.001), total bilirubin (weighted mean difference = 2.30 mmol/L, 95% CI = 1.24 to 3.36, *p* \< 0.001), and lower serum levels of albumin (weighted mean difference = − 4.24 g/L, 95% CI = − 6.20 to − 2.28, *p* \< 0.001) were associated with a significant increase in the severity of COVID-19 \[[@CR24]\].

COVID-19 in liver transplant patients {#Sec5}
=====================================

Studies regarding COVID-19 in liver transplant patients are limited. Maggi et al. showed that in 17 patients after liver transplant in Italy, two tested positive and one of whom died due to COVID-19 on postoperative day 30. However, 16 patients survived \[[@CR25]\]. Moreover, a similar study in Italy reported three of their 111 long-term liver transplant survivors died after infection with severe COVID-19. All three patients were male, older than 65 years, overweight (body mass index \[BMI\] \> 28 kg/m^2^), receiving antihypertensive medication, and had diabetes (median HbA~1c~ of 6·9%).They suggested liver transplant patients with metabolic comorbidities should be monitored closely, and also in concordance with the American Association for the Study of Liver Diseases, immunosuppression therapy should not be reduced or discontinued in asymptomatic recipients of liver transplant \[[@CR26], [@CR27]\].

Mechanism of action {#Sec6}
===================

It is undecided whether the hepatotoxicity of patients with COVID-19 is caused directly by viral infection of hepatocytes or by drug toxicity such as lopinavir/ritonavir, remdesivir, and chloroquine. Earlier ribonucleic acid (RNA) sequence data in the human protein atlas database has demonstrated low expression of the COVID receptor angiotensin converting enzyme 2 (ACE2) in liver, in addition to lung, which is the main target organ for COVID-19 and SARS \[[@CR28]\]. Chai et al. identified cholangiocyte specific expression of ACE2 through single-cell RNA sequencing in healthy human livers. They reported that the liver injury of SARS and COVID-19 patients may not be a result of hepatocyte damage, but cholangiocyte dysfunction and other causes such as drug-induced liver injury or a consequence of systemic inflammatory response \[[@CR29]\]. Gamma-glutamyl transferase, a diagnostic biomarker for cholangiocyte injury, has not been reported in the existing COVID-19 case studies; however, in an unpublished study by Zhang et al., found that GGT was elevated in 30 (54%) of 56 patients with COVID-19 during hospitalization \[[@CR1]\]. Xu et al. found moderate microvesicular steatosis and mild lobular and portal activity in liver biopsy of a COVID-19 patient. They proposed the injury could have been caused by either SARS-CoV-2 infection or drug-induced liver injury \[[@CR30]\]. Additionally, Liu et al. showed presence of hepatomegaly with dark red, hepatocyte degeneration with lobular necrosis and neutrophil infiltration, infiltration of monocytes and lymphocytes in the portal area, and congestion of hepatic sinuses with microthrombosis with no sign of bile duct injury or histological feature of hepatic failure in liver autopsy of critical COVID-19 \[[@CR31]\]. Li et al. demonstrated that in 148 patients with COVID-19, 50.7% had abnormal liver functions at admission, and they reported that the abnormal liver enzyme was significantly higher in cases who received lopinavir/ritonavir compared with patients with normal liver function test. Furthermore, a large number of infected patients had a history of taking antipyretic medication containing paracetamol, which can cause a transient hepatitis \[[@CR32]\]. Additional possibilities for the mild hepatitis may be due to hepatic congestion secondary to high levels of positive end-expiratory pressure which can contribute to increased right atrial pressures \[[@CR33]\]. Moreover, immune-mediated inflammation, for example cytokines and hypoxia related to pneumonia, might also contribute to liver injury in these patients \[[@CR1]\].

Conclusion {#Sec7}
==========

Liver enzymes are often elevated in COVID-19 patients, signifying liver damage. Recent data point to the fact that hepatotoxicity is more frequently occurring in severe COVID-19 cases compared with patients with mild disease. The underlying mechanism of hepatotoxicity in patients with COVID-19 could be due to systemic inflammation, drug-induced liver injury, or pre-existing chronic liver diseases. Current drugs prescribed to treat COVID-19 including oseltamivir, lopinavir/ritonavir, ribavirin, and chloroquine phosphate or hydroxychloroquine sulfate are metabolized in the liver. As a result, frequent and careful monitoring of liver function in patients with COVID-19 can lead to early diagnosis of hepatitis, liver injury, and liver failure. Further study should focus on the mechanisms of liver disease in COVID-19 and the impact of underlying chronic liver disease on treatment and outcome of COVID-19 in the future.
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